Eli Lilly’s shares have surged 750 per cent over five years. Novo Nordisk’s are up about 360 per cent in the same period.

These two pharmaceutical giants are positioned for growth with their innovative diabetes and obesity treatments.

NEW YORK (Reuters) -U.S. Senator Elizabeth Warren has asked antitrust regulators to scrutinize a $16.5 billion deal in which ...

Sen. Elizabeth Warren (D-MA) is calling on the Federal Trade Commission to carefully evaluate Novo Nordisk Foundation's ...

As Novo Holdings hopes to close its $16.5 billion acquisition of CDMO Catalent by the end of the year, the deal is facing a fresh round of lawmaker scrutiny. | In a letter to the chair of the U.S.

WW International, known as WeightWatchers, saw its stock soar on new of its new compounded GLP-1 offering. But analysts say that's only a short-term solution to its ailing business.

The surge in popularity of drugs like Ozempic, driven in part by its weight loss benefits, is contributing to a record-high ...

WeightWatchers (WW) is trying to save its ailing business by betting on a market that threatens its very existence. The ...

The novel GLP-1 receptor agonists will likely reduce the need for CABG and improve surgical outcomes, several argue.

If there’s a diet, Janet McCaskill says, she’s done it. “I’ve tried WeightWatchers. I’ve tried keto. I’ve gone to a ...

Senate Democrat Elizabeth Warren urges the Federal Trade Commission to closely scrutinize a proposed merger between Novo Nordisk and contract development and manufacturing organization Catalent, ...

Novo Holdings today announced that it has agreed to acquire a majority stake in Stingray Marine Solutions, a market-leading aquaculture technology ...